Combination targeted therapy with dabrafenib/trametinib, vemurafenib/cobimetinib, or encorafenib/binimetinib is recommended by the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) for metastatic or unresectable disease with a BRAF V600 mutation. Current targeted therapies have the potential to slow tumor growth (eg, BRAF inhibition) or release the brakes on the immune response, resulting in tumor lysis (eg, PD-1 inhibition).
Anti–PD-1 monotherapy with pembrolizumab or nivolumab is recommended in this setting for patients who do not have a BRAF V600 mutation.
Interferon alfa-2b was approved in 1995 for adjuvant treatment in patients who at high risk for recurrence after excision. However, although high-dose interferon alfa-2b and pegylated interferon have been shown to improve relapse-free survival, neither improves overall survival.
Access the NCCN Guidelines and Cutaneous Melanoma: ESMO Clinical Practice Guidelines for treatment of cancer.
Learn more about the treatment options for melanoma.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Chih-Shan Jason Chen. Fast Five Quiz: Melanoma Treatment - Medscape - Jan 24, 2020.